Davis Polk advised the sole structuring advisor and sole bookrunner in a Rule 144A offering by Impax Laboratories, Inc. of its 2.00% convertible senior notes due 2022. In addition, Davis Polk advised the counterparty to privately negotiated bond hedge and warrant transactions with Impax Laboratories in connection with the convertible senior notes offering.   

Impax Laboratories is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products.   

The Davis Polk corporate team included partner Deanna L. Kirkpatrick, counsel Jeffrey Gould and associate Varun Natteri Mangadu. The Davis Polk equity derivatives team included partner Ray Ibrahim and associates Barry J. Gewolb, Robert Stewart and Zuo (Zoey) Yi. Partner Po Sit and associate Brian Harris provided tax advice. Members of the Davis Polk team are based in the New York and Menlo Park offices.    

Copy link to share post